You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-Phospholipid Multiplex For Pathologic Epitopes

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): This project will help delineate the true nature of antigens in antiphospholipid syndrome (APS). Application of this knowledge would accelerate the pace of basic and clinical research as well as benefit tens of thousands of U.S. patients each year. Primary APS in some severe cases leads to death via emergency venous thrombosis/embolism; and secondary APS com ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Astrocyte-Restricted Precursors for Cell Therapy and Drug Screenin

    SBC: Q THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a cell therapy for the treatment of neurological disorders that are due to dysfunctional astrocytes. Current approaches to cure or manage these diseases by small molecule drugs are limited due to the polygenic and multifactorial nature of the disease. In addition, the blood brain barrier creates a significa ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Soft Hydrogels for Expansion of Quiescent Human MSCs

    SBC: GLYCOSAN BIOSYSTEMS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): An unmet need for expansion of primary cells and progenitor cells in three dimensions (3-D) is an extracellular matrix (ECM) substitute with user-controllable composition and compliance to which ECM proteins or synthetic peptides can be covalently attached by the end user. Glycosan BioSystems currently markets HyStem, an in situ-crosslinkable, semi-synthetic EC ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Noninvasive Multiple Inert Gas Elimination Technique

    SBC: MEDICAL PHYSICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Insufficient oxygenation of the blood (hypoxemia) is a common symptom in ICU patients, and may be caused by a combination of four different pathologies: 1) decreased alveolar ventilation (hypoventilation), 2) oxygen diffusion limitation, 3) inequality in ventilation/perfusion, and 4) shunts. Hypoxemia can be assessed by any of the following physiological parame ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Therapeutic Approach to Acute Lung Injury

    SBC: NAVIGEN, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): In our Phase 1 application, we described an endothelial specific receptor, Robo4, that is expressed in mature vessels and is upregulated following endothelial injury. Robo4, following activation by its protein ligand, Slit2, reduces agonist induced vascular leak in vitro and in vivo. We provided evidence of Slit2's efficacy in animal models of acute lung injury ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. SLIT2N for the treatment of influenza-induced acute respiratory distress

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Influenza infection leads to a cytokine storm as the host's immune system fights the virus. This combination of immunity factors has the unfortunate side effect of creating vascular leak. In the case of influenza patients, this vascular leak most often occurs in the lungs and can develop into acute respiratory distress syndrome (ARDS), a condition with high rat ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer

    SBC: JSK THERAPEUTICS INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Despite notable achievements over the past two decades, cancer remains a challenging 21st century epidemic demanding new, more effective drugs. Nitric oxide (NO) is well known to kill cancer cells without harming normal bone marrow cells, but until now has not been used directly to treat cancer because of its effect to lower blood pressure. JSK Therapeutics (J ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. A Parylene Ribbon Cable for Neural Prosthetic Applications

    SBC: BLACKROCK MICROSYSTEMS, INC            Topic: NIDCD

    DESCRIPTION (provided by applicant): This project addresses the process development and evaluation of an extremely flexible, Parylene C, micro-ribbon cable that is both biocompatible and biostable. Such a cable would be employed to link micro-electrode arrays with percutaneous connectors as well as with other in vivo micro-electronic arrays and modules. The key innovation is the approach utilized ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Discovery of drugs for use in the treatment and prevention of HIV infection using

    SBC: SYMBION DISCOVERY INCORPORATED            Topic: NCCAM

    DESCRIPTION (provided by applicant): Natural products are still the majority of therapeutic agents. However, they suffer from a difficulty in the creation of derivatives, and they can also be hard to supply. Derivatives are extremely important in the optimization of properties, such as toxicity or solubility, that are critical to development of therapeutics. Recently, it has become increasingly po ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Not Available

    SBC: KDT, LLC            Topic: NIEHS

    Toxic compounds are a major health hazard in our environment, in our food, and in our pharmaceuticals. Identifying toxic compounds is currently time-consuming, expensive and complicated by animal rights issues. We propose to generate a set of 96 transgenic nematodes that will contain fluorescent constructs that can measure activation of specific pathways. These strains can be used to categorize ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government